to determine whether specific antiplatelet therapies improved vein graft patency after coronary artery bypass grafting ( cabg ) we compared ( 1 ) aspirin , 325 mg daily , ( 2 ) aspirin , 325 mg three times daily , ( 3 ) aspirin plus dipyridamole ( 325 mg and 75 mg , respectively , three times daily ) , ( 4 ) sulfinpyrazone ( 267 mg three times daily ) , and ( 5 ) placebo ( three times daily ) .
C0004057
aspirin
C0732279
aspirin